Annual CFI
$74.23 M
+$64.60 M+670.64%
December 31, 2023
Summary
- As of February 12, 2025, EIGR annual cash flow from investing activities is $74.23 million, with the most recent change of +$64.60 million (+670.64%) on December 31, 2023.
- During the last 3 years, EIGR annual CFI has risen by +$119.02 million (+265.74%).
- EIGR annual CFI is now at all-time high.
Performance
EIGR Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$12.00 M
-$7.00 M-36.85%
December 31, 2023
Summary
- As of February 12, 2025, EIGR quarterly cash flow from investing activities is $12.00 million, with the most recent change of -$7.00 million (-36.85%) on December 31, 2023.
- Over the past year, EIGR quarterly CFI has dropped by -$9.80 million (-44.95%).
- EIGR quarterly CFI is now -87.30% below its all-time high of $94.46 million, reached on March 31, 2021.
Performance
EIGR Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$74.23 M
-$9.80 M-11.66%
December 31, 2023
Summary
- As of February 12, 2025, EIGR TTM cash flow from investing activities is $74.23 million, with the most recent change of -$9.80 million (-11.66%) on December 31, 2023.
- Over the past year, EIGR TTM CFI has increased by +$64.60 million (+670.64%).
- EIGR TTM CFI is now -11.66% below its all-time high of $84.03 million, reached on September 30, 2023.
Performance
EIGR TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
EIGR Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +670.6% | -45.0% | +670.6% |
| 3 y3 years | +265.7% | +144.5% | +265.7% |
| 5 y5 years | +355.2% | +32.3% | +550.7% |
EIGR Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +670.6% | -59.8% | +161.4% | -11.7% | +306.6% |
| 5 y | 5-year | at high | +265.7% | -87.3% | +126.4% | -11.7% | +265.7% |
| alltime | all time | at high | +221.3% | -87.3% | +117.0% | -11.7% | +208.6% |
Eiger BioPharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $74.23 M(+670.6%) | $12.00 M(-36.8%) | $74.23 M(-11.7%) |
| Sep 2023 | - | $19.00 M(-36.3%) | $84.03 M(+11.4%) |
| Jun 2023 | - | $29.85 M(+123.0%) | $75.41 M(+189.8%) |
| Mar 2023 | - | $13.38 M(-38.6%) | $26.02 M(+170.1%) |
| Dec 2022 | $9.63 M(-84.3%) | $21.80 M(+109.9%) | $9.63 M(-137.8%) |
| Sep 2022 | - | $10.38 M(-153.1%) | -$25.50 M(-21.7%) |
| Jun 2022 | - | -$19.55 M(+551.1%) | -$32.58 M(-9.3%) |
| Mar 2022 | - | -$3.00 M(-77.5%) | -$35.93 M(-158.4%) |
| Dec 2021 | $61.53 M(-237.4%) | -$13.33 M(-504.2%) | $61.53 M(+28.5%) |
| Sep 2021 | - | $3.30 M(-114.4%) | $47.90 M(-5870.8%) |
| Jun 2021 | - | -$22.90 M(-124.2%) | -$830.00 K(-101.7%) |
| Mar 2021 | - | $94.46 M(-450.3%) | $49.02 M(-209.5%) |
| Dec 2020 | -$44.79 M(+171.9%) | -$26.97 M(-40.6%) | -$44.79 M(-366.6%) |
| Sep 2020 | - | -$45.43 M(-268.5%) | $16.80 M(-55.0%) |
| Jun 2020 | - | $26.96 M(+4034.5%) | $37.35 M(-214.3%) |
| Mar 2020 | - | $652.00 K(-98.1%) | -$32.67 M(+98.4%) |
| Dec 2019 | -$16.47 M(-43.4%) | $34.62 M(-239.2%) | -$16.47 M(-60.8%) |
| Sep 2019 | - | -$24.87 M(-42.3%) | -$42.02 M(+68.8%) |
| Jun 2019 | - | -$43.07 M(-355.5%) | -$24.90 M(+13.3%) |
| Mar 2019 | - | $16.86 M(+85.8%) | -$21.98 M(-24.4%) |
| Dec 2018 | -$29.09 M | $9.07 M(-217.0%) | -$29.09 M(+1.5%) |
| Sep 2018 | - | -$7.75 M(-80.7%) | -$28.65 M(+159.1%) |
| Jun 2018 | - | -$40.16 M(-511.8%) | -$11.05 M(-131.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $9.75 M(+2.5%) | $34.76 M(+53.4%) |
| Dec 2017 | $22.66 M(-640.2%) | $9.51 M(-3.4%) | $22.66 M(-219.2%) |
| Sep 2017 | - | $9.84 M(+73.8%) | -$19.01 M(-34.2%) |
| Jun 2017 | - | $5.66 M(-340.3%) | -$28.89 M(-16.4%) |
| Mar 2017 | - | -$2.36 M(-92.7%) | -$34.56 M(+724.0%) |
| Dec 2016 | -$4.19 M(+9220.0%) | -$32.16 M(>+9900.0%) | -$4.19 M(-90.1%) |
| Sep 2016 | - | -$33.00 K(+175.0%) | -$42.45 M(+24.0%) |
| Jun 2016 | - | -$12.00 K(-100.0%) | -$34.23 M(+57.4%) |
| Mar 2016 | - | $28.01 M(-139.8%) | -$21.75 M(>+9900.0%) |
| Dec 2015 | -$45.00 K(-99.9%) | -$70.41 M(-959.8%) | -$45.00 K(-100.1%) |
| Sep 2015 | - | $8.19 M(-34.3%) | $80.19 M(+180.1%) |
| Jun 2015 | - | $12.47 M(-74.9%) | $28.63 M(-259.4%) |
| Mar 2015 | - | $49.71 M(+406.1%) | -$17.96 M(-70.6%) |
| Dec 2014 | -$61.19 M(-663.7%) | $9.82 M(-122.6%) | -$61.19 M(-10.4%) |
| Sep 2014 | - | -$43.37 M(+27.1%) | -$68.32 M(+267.2%) |
| Jun 2014 | - | -$34.13 M(-626.0%) | -$18.61 M(-213.0%) |
| Mar 2014 | - | $6.49 M(+141.5%) | $16.47 M(+51.8%) |
| Dec 2013 | $10.85 M(-149.7%) | $2.69 M(-57.6%) | $10.85 M(+32.9%) |
| Sep 2013 | - | $6.34 M(+562.0%) | $8.17 M(+347.3%) |
| Jun 2013 | - | $958.00 K(+10.4%) | $1.83 M(+110.4%) |
| Mar 2013 | - | $868.00 K | $868.00 K |
| Dec 2012 | -$21.83 M(<-9900.0%) | - | - |
| Dec 2011 | $0.00(-100.0%) | - | - |
| Jun 2011 | $35.00 K | - | - |
FAQ
- What is Eiger BioPharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Eiger BioPharmaceuticals?
- What is Eiger BioPharmaceuticals annual CFI year-on-year change?
- What is Eiger BioPharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Eiger BioPharmaceuticals?
- What is Eiger BioPharmaceuticals quarterly CFI year-on-year change?
- What is Eiger BioPharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Eiger BioPharmaceuticals?
- What is Eiger BioPharmaceuticals TTM CFI year-on-year change?
What is Eiger BioPharmaceuticals annual cash flow from investing activities?
The current annual CFI of EIGR is $74.23 M
What is the all time high annual CFI for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals all-time high annual cash flow from investing activities is $74.23 M
What is Eiger BioPharmaceuticals annual CFI year-on-year change?
Over the past year, EIGR annual cash flow from investing activities has changed by +$64.60 M (+670.64%)
What is Eiger BioPharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of EIGR is $12.00 M
What is the all time high quarterly CFI for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals all-time high quarterly cash flow from investing activities is $94.46 M
What is Eiger BioPharmaceuticals quarterly CFI year-on-year change?
Over the past year, EIGR quarterly cash flow from investing activities has changed by -$9.80 M (-44.95%)
What is Eiger BioPharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of EIGR is $74.23 M
What is the all time high TTM CFI for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals all-time high TTM cash flow from investing activities is $84.03 M
What is Eiger BioPharmaceuticals TTM CFI year-on-year change?
Over the past year, EIGR TTM cash flow from investing activities has changed by +$64.60 M (+670.64%)